Rosen Comments on Proposed New FDA Guidance on Drug-Device Combination Products
05 December 2017
Health Care on Bloomberg Law
Partner David Rosen is quoted in a Health Care on Bloomberg Law article, “FDA Seeks to Speed Approvals of Generic Drug-Device Combos,” about proposed new FDA guidance that will make it easier for generic companies to get drug-device combination products approved.
Rosen said the proposed guidance, which will allow a generic product to have certain labeling differences from the branded product if the labeling changes come from permitted design differences, could present safety issues.
“We have to make sure that there’s no potential for patient confusion, as well as caregiver confusion” if there are differences in the labeling, he said. “What we don’t want is something that is less safe or less effective than what is currently out there.”
Rosen said the proposed guidance, which will allow a generic product to have certain labeling differences from the branded product if the labeling changes come from permitted design differences, could present safety issues.
“We have to make sure that there’s no potential for patient confusion, as well as caregiver confusion” if there are differences in the labeling, he said. “What we don’t want is something that is less safe or less effective than what is currently out there.”
People
Related News
06 February 2025
In the News
Vanessa Miller Assesses Panama Canal Discourse
Foley & Lardner LLP partner Vanessa Miller commented in SupplyChainBrain article, "The Fight for Control of the Panama Canal," lending important context to the recent headlines over the important waterway.
06 February 2025
In the News
Gregory Husisian Weighs in on Suspension of De Minimis Trade Exemption
Foley & Lardner LLP partner Gregory Husisian offered context on President Trump's recent trade actions on China in The Wall Street Journal article, "Why Trump Is Closing a Trade Exemption for China."
04 February 2025
In the News
Andrew Wronski on Tariff Fluidity – 'Keep on top of the issues'
Foley & Lardner LLP partner Andrew Wronski assessed the evolving shift in U.S. trade policy in the Milwaukee Business Journal article, "Trump tariffs won't disappear — so how should Wisconsin businesses prepare?"